C4 Therapeutics (CCCC) Receivables (2019 - 2026)

C4 Therapeutics' Receivables history runs 8 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• On a quarterly basis, Receivables fell 64.09% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 64.09% decrease from a year earlier, with the FY2025 full-year figure at $2.4 million, down 22.6% from the prior year.
• Receivables improved to $2.9 million in Q1 2026 per CCCC's latest filing, from $2.4 million in the prior quarter.
• Across five years, Receivables topped out at $13.6 million in Q1 2024 and bottomed at $500000.0 in Q3 2023.
• The 5-year median for Receivables is $2.2 million (2025), against an average of $4.1 million.
• Across the five-year window, Receivables slumped 74.23% in 2022 and surged 2475.57% in 2024, its largest moves.
• Year by year, Receivables stood at $1.5 million in 2022, then soared by 701.02% to $11.8 million in 2023, then tumbled by 73.71% to $3.1 million in 2024, then retreated by 22.6% to $2.4 million in 2025, then grew by 20.07% to $2.9 million in 2026.
• Per Business Quant, the three latest CCCC Receivables figures stand at $2.9 million (Q1 2026), $2.4 million (Q4 2025), and $6.5 million (Q3 2025).